Meniere's Disease Treatment with Migraine Medications

This study is looking into whether two medications, nortriptyline and topiramate, can help improve symptoms of Meniere's disease. Meniere's disease is a condition that causes dizziness (vertigo), hearing loss, ringing in the ears (tinnitus), and a feeling of fullness in the ear. The study will compare nortriptyline and topiramate to another combination of medications, hydrochlorothiazide and triamterene. You might be able to join if you are between 25 and 85 years old, have active Meniere's disease, and can read and write in English. The main goal is to see if your Meniere's disease symptoms get better after 8 weeks of treatment. The current status of this study is unclear.

Study design
This is a double-blinded, randomized study with 40 participants. You would be assigned by chance to one of two treatment groups for 8 weeks.
What's involved
You would take medication once a day and attend weekly study visits for 8 weeks. An unblinded researcher will monitor your safety and advise on dosage changes.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 8 weeks, which is the duration of the study. It is not specified if there is follow-up after this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05582837

Treatment of Meniere's Disease With Migraine Medications

Recruiting
PHASE4Ages 25–85InterventionalTreatment
University of California, Irvine
~40 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:nortriptyline + topiramate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Subjective improvement of Meniere's Disease
Measured over 8 weeks
Ménière
1 sites across 1 states
California1
  • Hamid Djalilian, MD · PRINCIPAL_INVESTIGATOR · University of California, Irvine

Opens a ready-to-send draft in your own email app — review before sending.

  • Subjective improvement of Meniere's Disease8 weeks

    The primary outcome variable is derived from the validated Meniere's Disease Outcome Questionnaire (MDOQ) with 18 multiple-choice questions to compare quality of life before and after treatment. The question multiple choices are rated on a scale from 0 to 4 where the higher score indicates the higher quality of life. For each patient, the sum of his/her answers is divided (and x100) by the maximum possible scores for the pre-treatment questions and the post-treatment questions, separately. The outcome measure is the absolute change from pre- to post-treatment scores. Two-sample t test will be used to compare the outcome variable between the two treatment groups.